Breast cancer therapies reduce risk of Alzheimer’s disease and promote estrogenic pathways and action in brain
Gregory L. Branigan, Georgina Torrandell‐Haro, Shuhua Chen, Yuan Shang, Samantha Perez‐Miller, Zisu Mao, Marco Padilla‐Rodriguez, Helena Cortes‐Flores, Francesca Vitali, Roberta Dı́az Brinton
Abstract
Worldwide, an ever-increasing number of women are prescribed estrogen-modulating therapies (EMTs) for the treatment of breast cancer. In parallel, aging of the global population of women will contribute to risk of both breast cancer and Alzheimer's disease. To address the impact of anti-estrogen therapies on risk of Alzheimer's and neural function, we conducted medical informatic and molecular pharmacology analyses to determine the impact of EMTs on risk of Alzheimer's followed by determination of EMT estrogenic mechanisms of action in neurons. Collectively, these data provide both clinical and mechanistic data indicating that select EMTs exert estrogenic agonist action in neural tissue that are associated with reduced risk of Alzheimer's disease while simultaneously acting as effective estrogen receptor antagonists in breast.